A report from the National Poll on Healthy Aging reveals that more than half of older patients surveyed said their primary care providers have not asked them about their vision. Considering the number of ailments that can affect the aging population, vision is unfortunately often overlooked. This is concerning, since the incidence of age-related macular [Read More]
Category: Latest News
FTC Stops Deceptive Claims About Stem Cell Therapy
California companies lacked scientific evidence that their “amniotic stem cell therapy” could treat or cure macular degeneration and other serious diseases. A California-based physician and the two companies he controls have settled charges of deceptively advertising that “amniotic stem cell therapy” can treat serious diseases, including Parkinson’s disease, autism, macular degeneration, cerebral palsy, multiple sclerosis, [Read More]
Second Trial Showing Efficacy for Stem Cell Treatment of Dry AMD
A second trial begun in 2018 is showing positive results with replacing defective cells leading to vision loss from dry (geographic) macular degeneration. Implanted cells derived from stem cells have been implanted into five patients by researchers from University of Southern California (USC) and the University of California, Santa Barbara. Results at one year have [Read More]
Gout Associated With Increased Risk of AMD
A recent study by researchers at the University of Alabama at Birmingham School of Medicine, has looked into the association between age-related macular degeneration (AMD) and gout. Gout is a form of arthritis resulting from inflammation in the joints caused by the build-up of uric acid crystals and is associated with oxidative stress. The main [Read More]
Novel Gene Therapy In Trials for Wet AMD
(Updated 10/12/19) Adverum Biotechnologies, Inc. has announced progress with yet another therapy designed to extend the time between anti-VEGF injections for treatment of wet age-related macular degeneration (wAMD). The company’s Investigational New Drug (IND) application has been approved for a multi-center study of ADVM-022, a novel gene therapy candidate for the treatment of wAMD. “We [Read More]